D. Silasi

发表

MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer

R. Chen, G. Mor, D. Silasi, 2006, The Yale journal of biology and medicine.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2016, Molecular Cancer Therapeutics.

Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells

R. Chen, G. Mor, D. Silasi, 2008, Oncogene.

Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging

E. Ratner, D. Silasi, P. Schwartz, 2014, International Journal of Gynecologic Cancer.

TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.

R. Chen, G. Mor, D. Silasi, 2006, Cancer research.

In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Gynecologic Oncology.

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Molecular oncology.

Inflammation, Cancer and Chemoresistance: Taking Advantage of the Toll‐Like Receptor Signaling Pathway

R. Chen, G. Mor, D. Silasi, 2007, American journal of reproductive immunology.

Stem‐Like Ovarian Cancer Cells Can Serve as Tumor Vascular Progenitors

G. Mor, D. Silasi, A. Alvero, 2009, Stem cells.

Bevacizumab Related Hypertension and Reversible Posterior Leukoencephalopathy Syndrome in Gynecologic Malignancies: A Case Control Study

E. Ratner, D. Silasi, P. Schwartz, 2011 .

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

Gloria S. Huang, E. Ratner, R. Angioli, 2020, Oncotarget.

Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

E. Ratner, D. Silasi, P. Schwartz, 2011, American journal of obstetrics and gynecology.

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.

Gloria S. Huang, E. Ratner, Serena Wong, 2017, Gynecologic oncology.

Detection of cancer-related proteins in fresh-frozen ovarian cancer samples using laser capture microdissection.

R. Chen, G. Mor, D. Silasi, 2008, Methods in molecular biology.

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Gloria S. Huang, Abhijit A. Patel, D. Levine, 2018, Gynecologic oncology.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Scientific Reports.

Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor

D. Silasi, P. Schwartz, T. Rutherford, 2011, BMC Cancer.

Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes

E. Ratner, D. Silasi, P. Schwartz, 2019, Gynecologic and Obstetric Investigation.

Robotic-Assisted Laparoscopic Hysterectomy: Outcomes in Obese and Morbidly Obese Patients

D. Silasi, M. Azodi, Divya Patel, 2012, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

E. Ratner, D. Silasi, P. Schwartz, 2013, Clinical & Experimental Metastasis.

Transvaginal cholecystectomy versus single-incision laparoscopic cholecystectomy versus four-port laparoscopic cholecystectomy: a prospective cohort study

A. Duffy, D. Silasi, K. Roberts, 2012, Surgical Endoscopy.

A Simple Approach to Specimen Retrieval via Posterior Colpotomy Incision

D. Silasi, G. Menderes, M. Azodi, 2015, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).

L. Alexandrov, A. Iwasaki, E. Ratner, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

HER-2/NEU overexpression in vulvar Paget disease: the Yale experience

D. Silasi, P. Schwartz, T. Rutherford, 2010, Journal of Clinical Pathology.

HER‐2/neu receptor gene status in endometrial carcinomas: a tissue microarray study

D. Silasi, P. Schwartz, T. Rutherford, 2010, Histopathology.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2017, Clinical Cancer Research.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo

E. Ratner, D. Silasi, P. Schwartz, 2014, Cancer medicine.

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab

E. Ratner, D. Silasi, T. Rutherford, 2011, British Journal of Cancer.

Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs

G. Mor, D. Silasi, A. Alvero, 2009 .

Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor

D. Silasi, P. Schwartz, T. Rutherford, 2011, Clinical & Experimental Metastasis.

Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

E. Ratner, D. Silasi, P. Schwartz, 2014, International Journal of Gynecologic Cancer.

Comparison of Lymphedema Incidence Between 2 Lymphadenectomy Techniques in Patients With Uterine Cancer Undergoing Robotic Staging

D. Silasi, P. Schwartz, G. Menderes, 2015, International Journal of Gynecologic Cancer.

The significance of perineural invasion in early-stage cervical cancer.

E. Ratner, D. Silasi, J. Illuzzi, 2011, Gynecologic oncology.

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

E. Ratner, D. Silasi, T. Rutherford, 2014, British Journal of Cancer.

Carcinosarcoma of the ovary

G. Mor, D. Silasi, J. Illuzzi, 2007, International Journal of Gynecologic Cancer.

Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer

D. Silasi, G. Menderes, V. Parkash, 2019, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

Novel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model

G. Mor, T. Fahmy, D. Silasi, 2017, Scientific Reports.

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).

D. Silasi, P. Schwartz, T. Rutherford, 2013, American journal of obstetrics and gynecology.

High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of contemporary brachytherapy.

Influence of robotic-assisted laparoscopic hysterectomy on vaginal cuff healing and brachytherapy initiation in endometrial carcinoma patients.

D. Silasi, Henry S. Park, J. Stahl, 2016, Practical radiation oncology.

Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells

G. Mor, D. Silasi, A. Alvero, 2008, Oncogene.

Urinary hCG Screening in the Gynecologic Oncology Population

D. Silasi, P. Schwartz, T. Rutherford, 2011 .

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

S. Mane, T. Boggon, Kaya Bilgüvar, 2016, Proceedings of the National Academy of Sciences.

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.

Gloria S. Huang, G. Frampton, J. Newberg, 2019, Gynecologic oncology.

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015, Molecular Cancer Therapeutics.

Dual HER 2 / PIK 3 CA Targeting Overcomes Single-Agent Acquired Resistance in HER 2-Ampli fi ed Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015 .

Integrated mutational landscape analysis of uterine leiomyosarcomas

Gloria S. Huang, M. Imieliński, L. Alexandrov, 2021, Proceedings of the National Academy of Sciences.

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

Gloria S. Huang, R. Lifton, J. Schlessinger, 2018, Proceedings of the National Academy of Sciences.

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Pei Hui, Jonathan Black, David L Rimm, 2016, British Journal of Cancer.

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

R. Chen, G. Mor, D. Silasi, 2009, Cell cycle.

Regulation of Inflammation by the NF‐κB Pathway in Ovarian Cancer Stem Cells

G. Mor, D. Silasi, A. Alvero, 2011, American journal of reproductive immunology.

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines

F. Casagrande, D. Silasi, P. Schwartz, 2009, Journal of Virology.

Induction of human tumor‐associated differentially expressed gene‐12 (TADG‐12/TMPRSS3)‐specific cytotoxic T lymphocytes in human lymphocyte antigen‐A2.1–positive healthy donors and patients with advanced ovarian cancer

T. O'brien, S. Anfossi, D. Silasi, 2009, Cancer.

Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.

T. O'brien, S. Anfossi, D. Silasi, 2009, American journal of obstetrics and gynecology.

Gynecologic Malignancies in the Elderly

D. Silasi, P. Schwartz, T. Rutherford, 2011 .

Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer

Gloria S. Huang, E. Ratner, D. Silasi, 2018, Journal of Cancer Research and Clinical Oncology.

Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.

E. Ratner, D. Silasi, P. Schwartz, 2017, Gynecologic oncology.

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV)

Herbert Yu, D. Silasi, P. Schwartz, 2013, Journal of surgical oncology.

High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian Cancer

D. Rimm, G. Mor, D. Silasi, 2013, Reproductive Sciences.

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

A. Secord, E. Ratner, L. Havrilesky, 2020, Clinical Cancer Research.

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

A. Secord, E. Ratner, L. Havrilesky, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

F. Casagrande, D. Silasi, T. Rutherford, 2009, British Journal of Cancer.

Transvaginal Morcellation

D. Silasi, G. Menderes, V. Parkash, 2015, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

Robotic Versus Abdominal Hysterectomy for Very Large Uteri

D. Silasi, G. Menderes, M. Silasi, 2013, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

Robotic-Assisted Total Hysterectomy: Hysterectomy Techniques for the Large Uterus

D. Silasi, 2018 .

Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer

G. Mor, D. Silasi, A. Alvero, 2011, Journal of oncology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy

E. Ratner, D. Silasi, T. Rutherford, 2012, British Journal of Cancer.

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Gloria S. Huang, L. Alexandrov, A. Iwasaki, 2021, Cancer.

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

T. Boggon, Murim Choi, Shrikant Mane, 2013, Proceedings of the National Academy of Sciences.

Constitutive Proteasomal Degradation of TWIST-1 in Epithelial Ovarian Cancer Stem Cells Impacts Differentiation and Metastatic Potential

S. Nuti, G. Mor, D. Silasi, 2012, Oncogene.

Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment

G. Mor, D. Silasi, A. Alvero, 2013, Cancer Medicine.

Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment

G. Mor, D. Silasi, A. Alvero, 2013, Cancer medicine.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

E. Ratner, D. Silasi, P. Schwartz, 2013, Clinical & Experimental Metastasis.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

E. Ratner, D. Silasi, P. Schwartz, 2013, Clinical & Experimental Metastasis.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Gautam G. Rao, E. Ratner, D. Silasi, 2022, British Journal of Cancer.

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Gloria S. Huang, L. Alexandrov, T. Boggon, 2019, Proceedings of the National Academy of Sciences.

High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

D. Silasi, P. Schwartz, T. Rutherford, 2010, American journal of obstetrics and gynecology.

Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy

D. Silasi, P. Schwartz, T. Rutherford, 2009, International Journal of Gynecologic Cancer.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

E. Ratner, D. Silasi, T. Rutherford, 2015, Cancer.

Primary Cervical Carcinoma Cell Lines Overexpress Epithelial Cell Adhesion Molecule (EpCAM) and Are Highly Sensitive to Immunotherapy With MT201, a Fully Human Monoclonal Anti-EpCAM Antibody

F. Casagrande, D. Silasi, P. Schwartz, 2010, International Journal of Gynecologic Cancer.

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

E. Ratner, D. Silasi, P. Schwartz, 2020, Frontiers in Oncology.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Scientific Reports.

DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.

Gloria S. Huang, E. Ratner, D. Silasi, 2021, Gynecologic oncology.

Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)

F. Casagrande, D. Silasi, P. Schwartz, 2010, Molecular Cancer Therapeutics.

Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Gloria S. Huang, E. Ratner, E. Siegel, 2021, Gynecologic Oncology.

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma

G. Krikun, F. Casagrande, D. Silasi, 2010, British Journal of Cancer.

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer

E. Ratner, F. Casagrande, D. Silasi, 2009, British Journal of Cancer.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Transvaginal NOTES Hybrid Cholecystectomy

A. Duffy, D. Silasi, K. Roberts, 2012, Surgical innovation.

Pure Transvaginal Appendectomy Versus Traditional Laparoscopic Appendectomy for Acute Appendicitis: A Prospective Cohort Study

A. Duffy, D. Silasi, T. Rutherford, 2012, Annals of surgery.

Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic and Obstetric Investigation.

Minimally Invasive Ovarian-Preserving Approach for the Management of a Sclerosing Stromal Tumor in an Adolescent: A Case Report.

D. Silasi, R. A. Raad, A. Vash-Margita, 2022, Journal of pediatric and adolescent gynecology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

N. Rothman, Q. Lan, E. Ratner, 2015, British Journal of Cancer.

TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo

G. Mor, D. Silasi, A. Alvero, 2016, Molecular Cancer Therapeutics.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

E. Ratner, D. Silasi, M. Azodi, 2019, Scientific Reports.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

E. Sartori, E. Ratner, D. Silasi, 2017, Gynecologic oncology.

Automated Assay of a Four-Protein Biomarker Panel for Improved Detection of Ovarian Cancer

S. Drăghici, G. Mor, D. Silasi, 2021, Cancers.

Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.

Gloria S. Huang, E. Ratner, Serena Wong, 2017, Gynecologic oncology.

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Gynecologic oncology.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer

Gloria S. Huang, J. Schlessinger, E. Ratner, 2018, Clinical Cancer Research.

In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

Gloria S. Huang, E. Ratner, Serena Wong, 2018, Molecular Cancer Therapeutics.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

E. Ratner, W. Saltzman, D. Silasi, 2016, Molecular Cancer Therapeutics.

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody

Paola Todeschini, Masoud Azodi, Marta Betti, 2011, Journal of experimental & clinical cancer research : CR.

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo

E. Ratner, D. Silasi, P. Schwartz, 2017, Medical Oncology.

Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones

E. Ratner, D. Silasi, T. Rutherford, 2013, Cancer.

Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer

C. Zeiss, E. Ratner, W. Saltzman, 2015, International journal of cancer.

Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic Characteristics

E. Ratner, D. Silasi, P. Schwartz, 2014, International Journal of Gynecologic Cancer.

Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer

E. Ratner, D. Silasi, P. Schwartz, 2018, Gynecologic oncology reports.

Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer.

Masoud Azodi, E. Ratner, D. Silasi, 2012, Gynecologic oncology.

Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma

E. Ratner, D. Silasi, P. Schwartz, 2018, Reproductive Sciences.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

E. Ratner, D. Silasi, P. Schwartz, 2016, American journal of obstetrics and gynecology.

Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs.

G. Mor, D. Silasi, A. Alvero, 2009, Expert opinion on pharmacotherapy.

A survey of gynecologic oncologists regarding the end-of-life discussion: a pilot study.

E. Ratner, D. Silasi, J. Illuzzi, 2012, Gynecologic oncology.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Gynecologic oncology.

Benign multicystic mesothelioma: a case report of three sisters

D. Silasi, T. Rutherford, E. Bernstein, 2009, Rare tumors.

The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy.

D. Silasi, M. Azodi, K. Davis, 2015, Journal of minimally invasive gynecology.

The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy.

D. Silasi, M. Azodi, A. Tower, 2015, Journal of minimally invasive gynecology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer

B. Monk, P. Thaker, D. Silasi, 2023, International Journal of Gynecological Cancer.

Chronic hypertrophic vulvar herpes simulating neoplasia.

D. Silasi, V. Parkash, A. Domfeh, 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy

E. Siegel, E. Ratner, D. Silasi, 2013, British Journal of Cancer.

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer.

E. Ratner, D. Silasi, P. Schwartz, 2012 .

Supplementary Table 4a

E. Siegel, E. Ratner, D. Silasi, 2013 .

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

E. Ratner, D. Silasi, T. Rutherford, 2015, Cancer.

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Gloria S. Huang, Abhijit A. Patel, D. Levine, 2018, Gynecologic oncology.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.